Sobi Ramps Up In Rare Diseases With Apellis Deal

$250m Upfront Fee For Rights To Pegcetacoplan

 
• By Kevin Grogan
  
US dollars
Sobi spending big to boost portfolio • Source: Archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip